Correlation between baseline 18F-FDG PET/CT findings and CD38, CD138 expressing myeloma cells in bone marrow and clinical parameters in patiens with multiple myeloma

Cengiz, Arzu; Arda, Hayri Ustun; Doger, Firuzan Kacar; Yavaşoğlu, İrfan; Yürekli, Yakup

doi:10.4274/tjh.2017.0372

Cited by 8 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Cengiz et al reported that there was a significant correlation between bone marrow FDG uptake and percentage of CD38-and CD-138 expressing plasma cell. They also revealed the correlation between FDG uptake and some prognostically relevant laboratory parameters such as β2M and CRP [35]. As well the correlation between SUVmax in bone lesions and clinical parameters related to tumor burden such as high M protein, plasma cell >20% in bone marrow, β2M>3.5mg/dl, hypercalcemia at the onset of disease, and increased LDH was reported by Li et al [36].…”

Section: The Role Of Pet/ct In the Assessment Of Prognosismentioning

confidence: 56%

The Role of 18F-FDG-PET/CT Scan in the Management of Multiple Myeloma

Haghighat

2020

Asian Pac J Cancer Care

View full text Add to dashboard Cite

Bone lesion is a myeloma-defining event which is reported in 80% of multiple myeloma patients. Imaging of bone is essential in the evaluation of pattern and extent of bone involvement. Recently, whole body X ray (WBXR) has been replaced by more accurate imaging such as whole bode MRI and FDG-PET/CT scan. This review article provides the advantages and role of PET/CT scan in the diagnosis and management of multiple myeloma patients. Generally, PET/CT in diagnosis of bone involvement of newly diagnosed myeloma patients is more sensitive than WBXR. The prognostic value of PET/CT in newly diagnosed patients has been described as well. Different studies have demonstrated that several PET parameters such as the number of focal lesions (FL), SUVmax and extramedullary disease(EMD) may affect the outcome of multiple myeloma patients. Interstingely, the main role of PET/CT in myeloma patients is treatment response monitoring and to some extent assessment of MRD. PET/CT appears to be superior than MRI in evaluation of response due to its ability in differentiating active lesion from negative one.

show abstract

Section: The Role Of Pet/ct In the Assessment Of Prognosismentioning

confidence: 56%

The Role of 18F-FDG-PET/CT Scan in the Management of Multiple Myeloma

Haghighat

2020

Asian Pac J Cancer Care

View full text Add to dashboard Cite

show abstract

“…Previous studies reported a correlation between FDG uptake by BM and PC in ltration [12,20,28,29,[42][43][44][45], while others showed that FDG uptake correlated with b2m [28,29] and CRP (29) and negatively correlated with Hb and HT [29] as well as Alb [28].…”

Section: Discussionmentioning

confidence: 96%

“…Regarding the semi-quantitative evaluation, the SUV max of the ROI, namely, the right anterior iliac crest, was calculated using semiautomatic image registration software package. The right anterior iliac crest was selected to standardize the calculation of FDG uptake by BM because it was the biopsy site and concordant with previous studies [12,28,29]. Figures 1 and 2 demonstrates the PET/CT scan image of MM patients.…”

Section: F-fdg Pet/ct Imagingmentioning

confidence: 88%

Relationship Between Fluorine-18 Fluorodeoxyglucose PET/CT Uptake and the Plasma Cell Infiltration Rate in the Bone Marrow of Patients With Multiple Myeloma

Ganbold¹,

Nakagami²,

Inamura³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The present study investigated the relationship between maximum standardized uptake values (SUVmax) on Fluorine-18 Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and the plasma cell (PC) proliferation percentage in the bone marrow (BM) of patients with multiple myeloma (MM).Material and methods: Patients clinically and pathologically diagnosed with MM between January 2012 and October 2019 were selected from the database of Dokkyo Medical University Hospital (DMU Hospital), Japan. Patients with other malignancies and those who received chemotherapy and radiation therapy or hematopoietic treatments in the previous 4 weeks and 2-3 months prior to PET/CT scans were excluded from the present study to avoid false uptake. We examined 60 patients (female: male; 27:33; 1:1.22) aged between 37 and 91 years; mean ± SD; 67.3 ± 10.2 years. Hematological and biochemical tests with results on hemoglobin (Hb), hematocrit (Ht), C reactive protein (CRP), beta-2 microglobulin (b2m), creatinine (Cre), albumin (Alb), calcium (Ca), white blood cells (WBC), and red blood cells (RBC) were recorded and evaluated. The percentage of PC in BM biopsy samples was calculated. On PET/CT images, the SUVmax of the region of interest (ROI) of the right anterior iliac crest, the biopsy site, was measured. Relationships were examined using Pearson’s correlation coefficient with SPSS.Results: The types of MM diagnosed were IgGk in 31 patients (51.6%), IgGλ in 19 (31.6%), IgAλ in 5 (8.3%), IgAk in 2 (3.3%), IgDλ in 2 (3.3%), and IgDk in 1 (1.6%). According to the Durie-Salmon staging system, 4 patients had stage I, 6 stage II, and 33 stage III, while stages were not recorded in the remaining 17 patients. A positive correlation was observed between FDG uptake and the percentage of PC (r=0.7, p<0.001), but not between FDG uptake and hematological and biochemical parameters in all patients. However, a correlation was observed between FDG uptake and b2m (r=0.596, p=0.004) in 21 patients (35%).Conclusion: Increased FDG uptake by BM correlated with the percentage of PC. PET/CT is crucial for the diagnosis, treatment evaluation, and follow-up of MM patients.

show abstract

“…On the other hand, in the literature there are a few studies demonstrating a negative correlation between PET-CT parameters and HB. [ 30 , 31 ] However, those studies were conducted in patients with multiple myeloma. The negative correlations observed in these studies may be related to multiple myeloma itself.…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of tumor/lymph node standardized uptake value max ratio and correlation with hematologic parameters in stage III nonsmall cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Stage III non-small cell lung cancer (NSCLC) is a highly heterogeneous subtype of lung cancer. There are still no widely accepted prognostic parameters for stage III NSCLC. In this study, we evaluated the prognostic value of the standardized uptake value (SUV) max ratio of primary tumor to lymph node (T/N SUV max) and its correlation with various hematological parameters. Patient data were reviewed from the hospital database retrospectively. The T/N SUV max ratio was calculated by dividing the SUV max of the primary tumor by the maximal SUV max of the lymph node. The cut-off value for T/N SUV max ratio was determined by receiver operating characteristic analysis. Survival analysis was performed by Kaplan–Meier method with the Long-rank test. P value < .05 was considered statistically significant. A total of 52 patients were included in this study. The optimal cut-off value for T/N SUV max was 1.96 (area under the curve: 0.74; 72.7% sensitivity and 73.7% specificity). Patients with T/N SUV max ≤1.96 were defined as high risk patients and those with >1.96 were defined as low risk patients. The median event (recurrence or progression) free survival was 24.3 months (95% confidence interval: 12.0–36.6) for low risk patients, and 9.2 months (95% confidence interval: 6.1–12.4) for high risk patients ( P = .0015). There was an inverse correlation between T/N SUV max and hemoglobin concentration and mean corpuscular volume (rho: −0.349, P = .011; rho: −0.312, P = .025, respectively). Low risk patients had a more favorable prognosis compared to high risk patients. We demonstrated that T/N SUV max can be of prognostic value in stage III NSCLC. T/N SUV max correlated only with hemoglobin and mean corpuscular volume.

show abstract

Correlation between baseline 18F-FDG PET/CT findings and CD38, CD138 expressing myeloma cells in bone marrow and clinical parameters in patiens with multiple myeloma

Cited by 8 publications

References 27 publications

The Role of 18F-FDG-PET/CT Scan in the Management of Multiple Myeloma

The Role of 18F-FDG-PET/CT Scan in the Management of Multiple Myeloma

Relationship Between Fluorine-18 Fluorodeoxyglucose PET/CT Uptake and the Plasma Cell Infiltration Rate in the Bone Marrow of Patients With Multiple Myeloma

The prognostic value of tumor/lymph node standardized uptake value max ratio and correlation with hematologic parameters in stage III nonsmall cell lung cancer

Contact Info

Product

Resources

About

Correlation between baseline 18F-FDG PET/CT findings and CD38, CD138 expressing myeloma cells in bone marrow and clinical parameters in patiens with multiple myeloma

Cited by 8 publications

References 27 publications

The Role of 18F-FDG-PET/CT Scan in the Management of Multiple Myeloma

The Role of 18F-FDG-PET/CT Scan in the Management of Multiple Myeloma

Relationship Between Fluorine-18&nbsp;Fluorodeoxyglucose PET/CT Uptake and the Plasma Cell Infiltration Rate in the Bone Marrow of Patients With Multiple Myeloma

The prognostic value of tumor/lymph node standardized uptake value max ratio and correlation with hematologic parameters in stage III nonsmall cell lung cancer

Contact Info

Product

Resources

About

Relationship Between Fluorine-18 Fluorodeoxyglucose PET/CT Uptake and the Plasma Cell Infiltration Rate in the Bone Marrow of Patients With Multiple Myeloma